Abstract
Purpose De novo variants in CUL3 (Cullin-3 ubiquitin ligase) have been strongly associated with neurodevelopmental disorders (NDDs), but no large case series have been reported so far. Here we aimed to collect sporadic cases carrying rare variants in CUL3, describe the genotype-phenotype correlation, and investigate the underlying pathogenic mechanism.
Methods Genetic data and detailed clinical records were collected via multi-center collaboration. Dysmorphic facial features were analyzed using GestaltMatcher. Variant effects on CUL3 protein stability were assessed using patient-derived T-cells.
Results We assembled a cohort of 35 individuals with heterozygous CUL3 variants presenting a syndromic NDD characterized by intellectual disability with or without autistic features. Of these, 33 have loss-of-function (LoF) and two have missense variants. CUL3 LoF variants in patients may affect protein stability leading to perturbations in protein homeostasis, as evidenced by decreased ubiquitin-protein conjugates in vitro. Specifically, we show that cyclin E1 (CCNE1) and 4E-BP1 (EIF4EBP1), two prominent substrates of CUL3, fail to be targeted for proteasomal degradation in patient-derived cells.
Conclusion Our study further refines the clinical and mutational spectrum of CUL3-associated NDDs, expands the spectrum of cullin RING E3 ligase-associated neuropsychiatric disorders, and suggests haploinsufficiency via LoF variants is the predominant pathogenic mechanism.
Competing Interest Statement
E.E.E. is a scientific advisory board (SAB) member of Variant Bio, Inc. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing completed at Baylor Genetics Laboratories. The other authors declare no conflict of interest.
Funding Statement
Funding for the project was provided by the Wellcome Trust. We are grateful to Anne Brandenburg for excellent technical assistance. F.E. receives support from the French National Research Agency under the Programme Investissement dAvenir (NExT (I-SITE), project NDD-UBIPRO). J.L.E. was funded by the McLaughlin Centre (grant #MC-2012-13, #MC-2014-11-1, and MC-2017-12) and CIHR-Champions of Genetics: Building the Next Generation Grant (FRN: 135730). J.A.M. was funded by the National Human Genome Research Institute grant R01 HG009141. Both J.L.E. And J.A.M acknowledge support for sequencing and analysis through the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) which is funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900. J.W. and M.Z. receive research support from the German Research Foundation (DFG 458949627; WI 1820/14-1; ZE 1213/2-1). F.L. and A.G. were co-supported by Recherche Innovation Normandie (RIN 2018) and the European Regional Development Fund (ERDF). M.T. and F.C.R. receive support from AIRC (IG 21614, to M.T.), EJP-RD (NSEuroNet, to M.T.), and Italian Ministry of Health (5×1000_2019 and CCR-2017-23669081, to M.T.; and GR-2019-12371203, to F.C.R.). E.W.K. is supported by the Center for Individualized Medicine and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. This study was supported, in part, by the Fundamental Research Funds for the Central Universities starting fund (BMU2022RCZX038) to T.W., the US National Institutes of Health (NIH) grant R01MH101221 to E.E.E., and the National Natural Science Foundation of China (82201314) to T.W. E.E.E. is an investigator of the Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was designed and initiated while P.B. was at the Mayo Clinic. Ethical approval for the study was provided by the Mayo Clinic Institutional Review Board (IRB# 12-009346). F.E. performed functional investigations on human samples which were approved by the ethics board of the Universitatsmedizin Greifswald (Ethics number BB 014/14). Patient consent for participation and phenotyping was obtained through each of the referring clinicians and centers. Clinical records including information related to neurodevelopmental, behavioral, dysmorphology, and other related phenotypic features were collected. Consent for collection of patient blood samples and clinical information, including patient photos, was further obtained in accordance with the recognized standards of the Declaration of Helsinki and approved by local Institutional Review Boards at the referring institutions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All of the patient variant and phenotype data used in this study has been provided in the tables, or relevant supplementary tables.
